Advertisement

Topics

Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures

09:43 EST 23 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Rosetta Genomics Ltd. (NASDAQ:ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces the closing of the second tranche of the priva...

Other Sources for this Article

Rosetta Genomics:
Ken Berlin, 267-298-1159
President & CEO
investors@rosettagx.com
or
Rosetta Genomics Investors:
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com

NEXT ARTICLE

More From BioPortfolio on "Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures"

Advertisement
Quick Search
Advertisement
Advertisement